# Cardiff Oncology, Inc. (CRDF) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Cardiff Oncology, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/CRDF/mda/fy2025/): filed 2026-02-24; accession 0001193125-26-067464 (https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/CRDF/mda/fy2024/): filed 2025-02-27; accession 0000950170-25-028992 (https://www.sec.gov/Archives/edgar/data/1213037/000095017025028992/crdf-20241231.htm)
- [FY 2023 MD&A](/company/CRDF/mda/fy2023/): filed 2024-02-29; accession 0001628280-24-007948 (https://www.sec.gov/Archives/edgar/data/1213037/000162828024007948/crdf-20231231.htm)
- [FY 2022 MD&A](/company/CRDF/mda/fy2022/): filed 2023-03-02; accession 0001628280-23-006037 (https://www.sec.gov/Archives/edgar/data/1213037/000162828023006037/crdf-20221231.htm)
- [FY 2021 MD&A](/company/CRDF/mda/fy2021/): filed 2022-02-24; accession 0001628280-22-003808 (https://www.sec.gov/Archives/edgar/data/1213037/000162828022003808/crdf-20211231.htm)

Back to /company/CRDF/